newsfilter
← Earnings
Earnings Releases·

Zai Lab — Third Quarter 2026 Earnings Summary

  • Total revenue declined 7% year-over-year to $108.2 million in Q3 2026, driven by OPTUNE competition and a $13.6 million inventory write-down that expanded the net loss to $46.1 million ($0.41 per ADS).
  • The company anticipates 2027 as a pivotal year for growth, targeting multiple U.S. BLA submissions for zoci and ZL-1503, alongside a return to China business growth.
  • Zoci advanced to a global Phase 3 study in 1L ES-SCLC by year-end 2026 following compelling ESMO 2026 data, while partner argenx reported positive Phase 3 results for VYVGART in autoimmune myositis.
  • A private placement of 11.34 million ADSs closed on October 27, 2026, generating approximately $241.2 million in net proceeds to fund pipeline development and working capital.
Company
ZAI LAB LTD
Sector
Healthcare
Industry
Biotechnology